vs
爵士制药（JAZZ）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是RANGE RESOURCES CORP的1.5倍（$1.2B vs $786.9M），RANGE RESOURCES CORP净利率更高（22.8% vs 17.0%，领先5.8%），RANGE RESOURCES CORP同比增速更快（18.0% vs 10.1%），过去两年爵士制药的营收复合增速更高（15.2% vs 14.6%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
JAZZ vs RRC — 直观对比
营收规模更大
JAZZ
是对方的1.5倍
$786.9M
营收增速更快
RRC
高出7.9%
10.1%
净利率更高
RRC
高出5.8%
17.0%
两年增速更快
JAZZ
近两年复合增速
14.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $786.9M |
| 净利润 | $203.5M | $179.1M |
| 毛利率 | — | 94.5% |
| 营业利润率 | 21.2% | — |
| 净利率 | 17.0% | 22.8% |
| 营收同比 | 10.1% | 18.0% |
| 净利润同比 | 6.5% | 88.8% |
| 每股收益（稀释后） | $3.34 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRRC
| Q4 25 | $1.2B | $786.9M | ||
| Q3 25 | $1.1B | $655.3M | ||
| Q2 25 | $1.0B | $699.6M | ||
| Q1 25 | $897.8M | $846.3M | ||
| Q4 24 | $1.1B | $667.0M | ||
| Q3 24 | $1.1B | $567.9M | ||
| Q2 24 | $1.0B | $513.2M | ||
| Q1 24 | $902.0M | $598.8M |
净利润JAZZRRC
| Q4 25 | $203.5M | $179.1M | ||
| Q3 25 | $251.4M | $144.3M | ||
| Q2 25 | $-718.5M | $237.6M | ||
| Q1 25 | $-92.5M | $97.1M | ||
| Q4 24 | $191.1M | $94.8M | ||
| Q3 24 | $215.1M | $50.7M | ||
| Q2 24 | $168.6M | $28.7M | ||
| Q1 24 | $-14.6M | $92.1M |
毛利率JAZZRRC
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
营业利润率JAZZRRC
| Q4 25 | 21.2% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -65.6% | — | ||
| Q1 25 | -6.2% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 7.3% | — |
净利率JAZZRRC
| Q4 25 | 17.0% | 22.8% | ||
| Q3 25 | 22.3% | 22.0% | ||
| Q2 25 | -68.7% | 34.0% | ||
| Q1 25 | -10.3% | 11.5% | ||
| Q4 24 | 17.6% | 14.2% | ||
| Q3 24 | 20.4% | 8.9% | ||
| Q2 24 | 16.5% | 5.6% | ||
| Q1 24 | -1.6% | 15.4% |
每股收益（稀释后）JAZZRRC
| Q4 25 | $3.34 | $0.75 | ||
| Q3 25 | $4.08 | $0.60 | ||
| Q2 25 | $-11.74 | $0.99 | ||
| Q1 25 | $-1.52 | $0.40 | ||
| Q4 24 | $2.97 | $0.38 | ||
| Q3 24 | $3.42 | $0.21 | ||
| Q2 24 | $2.49 | $0.12 | ||
| Q1 24 | $-0.23 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $204.0K |
| 总债务越低越好 | $5.4B | $1.2B |
| 股东权益账面价值 | $4.3B | $4.3B |
| 总资产 | $11.7B | $7.4B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资JAZZRRC
| Q4 25 | $1.4B | $204.0K | ||
| Q3 25 | $1.3B | $175.0K | ||
| Q2 25 | $1.2B | $134.0K | ||
| Q1 25 | $1.9B | $344.6M | ||
| Q4 24 | $2.4B | $304.5M | ||
| Q3 24 | $2.2B | $277.4M | ||
| Q2 24 | $1.4B | $251.1M | ||
| Q1 24 | $1.4B | $343.1M |
总债务JAZZRRC
| Q4 25 | $5.4B | $1.2B | ||
| Q3 25 | $5.4B | $1.2B | ||
| Q2 25 | $5.4B | $1.2B | ||
| Q1 25 | $5.4B | $1.7B | ||
| Q4 24 | $6.1B | $1.7B | ||
| Q3 24 | $6.1B | $1.7B | ||
| Q2 24 | $5.7B | $1.7B | ||
| Q1 24 | $5.7B | $1.8B |
股东权益JAZZRRC
| Q4 25 | $4.3B | $4.3B | ||
| Q3 25 | $4.0B | $4.2B | ||
| Q2 25 | $3.7B | $4.1B | ||
| Q1 25 | $4.2B | $3.9B | ||
| Q4 24 | $4.1B | $3.9B | ||
| Q3 24 | $4.2B | $3.9B | ||
| Q2 24 | $3.8B | $3.9B | ||
| Q1 24 | $3.7B | $3.8B |
总资产JAZZRRC
| Q4 25 | $11.7B | $7.4B | ||
| Q3 25 | $11.4B | $7.2B | ||
| Q2 25 | $10.9B | $7.1B | ||
| Q1 25 | $11.5B | $7.4B | ||
| Q4 24 | $12.0B | $7.3B | ||
| Q3 24 | $12.3B | $7.2B | ||
| Q2 24 | $11.4B | $7.3B | ||
| Q1 24 | $11.3B | $7.4B |
负债/权益比JAZZRRC
| Q4 25 | 1.24× | 0.28× | ||
| Q3 25 | 1.35× | 0.29× | ||
| Q2 25 | 1.45× | 0.29× | ||
| Q1 25 | 1.29× | 0.43× | ||
| Q4 24 | 1.49× | 0.43× | ||
| Q3 24 | 1.47× | 0.44× | ||
| Q2 24 | 1.52× | 0.44× | ||
| Q1 24 | 1.54× | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | — |
| 自由现金流率自由现金流/营收 | 28.9% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.78× | 1.44× |
| 过去12个月自由现金流最近4个季度 | $1.3B | — |
8季度趋势，按日历期对齐
经营现金流JAZZRRC
| Q4 25 | $362.5M | $257.5M | ||
| Q3 25 | $474.6M | $247.5M | ||
| Q2 25 | $88.9M | $336.2M | ||
| Q1 25 | $429.8M | $330.1M | ||
| Q4 24 | $398.6M | $217.9M | ||
| Q3 24 | $398.7M | $245.9M | ||
| Q2 24 | $331.4M | $148.8M | ||
| Q1 24 | $267.2M | $331.9M |
自由现金流JAZZRRC
| Q4 25 | $345.8M | — | ||
| Q3 25 | $459.4M | — | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $415.9M | — | ||
| Q4 24 | $385.3M | — | ||
| Q3 24 | $388.0M | — | ||
| Q2 24 | $324.3M | — | ||
| Q1 24 | $260.3M | — |
自由现金流率JAZZRRC
| Q4 25 | 28.9% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 46.3% | — | ||
| Q4 24 | 35.4% | — | ||
| Q3 24 | 36.8% | — | ||
| Q2 24 | 31.7% | — | ||
| Q1 24 | 28.9% | — |
资本支出强度JAZZRRC
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.8% | — |
现金转化率JAZZRRC
| Q4 25 | 1.78× | 1.44× | ||
| Q3 25 | 1.89× | 1.72× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | 2.09× | 2.30× | ||
| Q3 24 | 1.85× | 4.85× | ||
| Q2 24 | 1.97× | 5.18× | ||
| Q1 24 | — | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
